Pre-clinical Results with RNAi Therapeutics for Cardiovascular Metabolic Disease at ATVB 2014

Pre-clinical Results with RNAi Therapeutics for Cardiovascular Metabolic Disease at ATVB 2014

We have presented new pre-clinical data from our growing pipeline of RNAi therapeutics for the treatment of cardiovascular metabolic disease, including ALN-PCSsc targeting PCSK9 for the treatment of hypercholesterolemia, and a newly named program, ALN-AC3 targeting apolipoprotein C-III (apoCIII) for the treatment of hypertriglyceridemia.  The data were presented in an oral presentation at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions held May 1-3, 2014 in Toronto, Ontario.

New data in non-human primates demonstrated that a single dose of ALN-PCSsc significantly reduced plasma PCSK9 protein by up to 96%, with mean PCSK9 knockdown at nadir of 88% at the top dose.  Results also showed lowering of LDL-C of up to 77%, with a mean reduction of 69% at the top dose.  These results were observed in the absence of statin co-administration.  In addition, knockdown of PCSK9 and lowering of LDL-C were rapid and durable, with maximal effects lasting greater than 90 days and returning to baseline at approximately 160 days.  At the top dose, an over 50% reduction in LDL-C was maintained for over 90 days.  These data support a once-monthly and possibly a once-quarterly subcutaneous dosing regimen, which represents what should be a highly competitive profile with anti-PCSK9 monoclonal antibodies.  We plan to advance ALN-PCSsc, which is partnered with The Medicines Company, toward clinical trials by the end of this year or early next.

In addition, we presented rodent data with ALN-AC3 – our newly named GalNAc-siRNA conjugate targeting apoCIII – showing up to 95% knockdown of apoCIII and up to 68% reduction in triglycerides.  These results warrant further efforts to advance this new RNAi therapeutic program into later stages of development.






Receive news and updates on the work at Alnylam that affects you most.